Entrada stock falls on Duchenne data; Wegovy expands access

May 7, 2026 11:04 AM EDT News Briefing En­tra­da stock falls on Duchenne da­ta; We­govy ex­pands ac­cess ENDPOINTS Plus, news about BioCryst, GSK and Roche. 🙃 En­tra­da’s Duchenne drug dis­ap­points: The biotech re­port­ed ini­tial da­ta in six pa­tients who … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER